Antidepressant fluoxetine and its potential against colon tumors

doi:10.4251/wjgo.v6.i1.11

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7464)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

496

WORD

397

HTML

4079

Figures (1-5)

253

Sum=5225

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1125

Download

1114

Sum=2239

Jan 15, 2014 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jan 15, 2014; 6(1): 11-21
Published online Jan 15, 2014. doi: 10.4251/wjgo.v6.i1.11

Antidepressant fluoxetine and its potential against colon tumors

Helga Stopper, Sergio Britto Garcia, Ana Maria Waaga-Gasser, Vinicius Kannen

Helga Stopper, Vinicius Kannen, Department of Toxicology, University of Wuerzburg, D-97078 Wurzburg, Germany

Sergio Britto Garcia, Department of Pathology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-902, Brazil

Ana Maria Waaga-Gasser, Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg, D-97078 Wuerzburg, Germany

Supported by German Academic Exchange Service (DAAD), National Council for Scientific and Technological Development (CNPQ); and Foundation for Research Support of the State of São Paulo (FAPESP)

Author contributions: Stoppe H, Garcia SB, and Waaga-Gasser AM contributed with unpublished data and discussions; Kannen V conceived and wrote this manuscript.

Correspondence to: Vinicius Kannen, PhD, Department of Toxicology, University of Wuerzburg, Versbacher Strasse 9, D-97078 Wuerzburg, Germany. vinicius.cardoso@uni-wuerzburg.de

Telephone: +49-931-86133 Fax: +49-931-86133

Received: September 20, 2013
Revised: November 9, 2013
Accepted: December 9, 2013
Published online: January 15, 2014
Processing time: 117 Days and 11.8 Hours

Core Tip

Core tip: It is currently thought that aerobic glycolysis is key for understanding cell survival in the hostile tumor microenvironment. Then, the antidepressant fluoxetine (FLX) has been shown to reduce colon tumor growth in animals and colon cancer incidence in humans. Here, we explore new perspectives of FLX reducing the development of colon tumors through a blockage in tumor metabolism. This perspective review is based on our current unpublished experimental dataset which shows FLX as a potential co-chemotherapeutic agent for colon cancer therapy.